Maria Florencia Giraudo
Thesis Title
TBD
Publications
- Giraudo, M. F., Jackson, Z., Das, I., Abiona, O. M., & Wald, D. N. (2024). Chimeric Antigen Receptor (CAR)-T Cell Therapy for Non-Hodgkin's Lymphoma. Pathogens & immunity, 9(1), 1–17. https://doi.org/10.20411/pai.v9i1.647
- Kleinsorge-Block, S., Giraudo, M., Idipilly, N., Caley, D., Reese-Koc, J., Arunachalam, A., Chaekal, O., Sheets, M., Purgert, R., Melenhorst, J., Farooq, U., Caimi, P., Deng, C., Wald, D., Besien, K.van., Gallogly, M. (2025). Development and Clinical Validation of a Less Than 1 Day Car-T Manufacturing Process. Cytotherapy 27.5: S15. Print. https://doi.org/10.1016/j.jcyt.2025.03.016
- Lee, G., Schauner, R., Burke, J., Borocz, J., Vasana, S., Sobieraj, L., Giraudo, M., Jackson, Z., Ansari, Q., Navas, M., Sakr, H., & Wald, D. (2023). NK cells from COVID-19 positive patients exhibit enhanced cytotoxic activity upon NKG2A and KIR2DL1 blockade. Frontiers in immunology, 14, 1022890. https://doi.org/10.3389/fimmu.2023.1022890
- Stadel, R., Idippily, N., Giraudo, M. F., Caimi, P., Van Besien, K., Martin, J., Wu, J., Deng, C., & Wald, D. (2023). Development and clinical validation of an ultra-fast CAR-T manufacturing platform enabling production of CAR-T cells in less than 1 day. Blood, 142(Supplement 1), 4848–4848. https://doi.org/10.1182/blood-2023-188214
- Jackson, Z., Hong, C., Schauner, R., Dropulic, B., Caimi, P. F., de Lima, M., Giraudo, M. F., Gupta, K., Reese, J. S., Hwang, T. H., & Wald, D. N. (2022). Sequential Single-Cell Transcriptional and Protein Marker Profiling Reveals TIGIT as a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin Lymphoma. Cancer discovery, 12(8), 1886–1903. https://doi.org/10.1158/2159-8290.CD-21-1586
Professional/Educational Meetings/Abstracts
- Intersections: Symposium and Poster Session (2022)
- Leadership Alliance National Symposium (2021)
- University of Pennsylvania SUIP Symposium (2021)